STOCKHOLM, SWEDEN--(Marketwire - August 21, 2008) - The fourth annual Swedish-American Life
Science Summit (SALSS) opens in Stockholm, Sweden on August 20, 2008. The
intense and exclusive two-day program (Aug 20-22) takes place against a
backdrop of major scientific breakthroughs and a volatile business economy.
"It is our hope and ambition that the summit will serve to increase the
amount of cross-border business between the United States, the largest
healthcare market in the world, and Sweden, one of the most important Life
Science industry centers in Europe, and extend that footprint to other key
global centers," says Barbro C. Ehnbom, founder and chairman of SALSS. Ms.
Ehnbom has held top level positions on Wall Street and in the
pharmaceutical industry and has a long and extensive experience in
Swedish-American investment banking.
Against the uncertainties of the life science business and the
unpredictable economic climate, the need for collaborative problem solving
is greater than ever. The Fourth SALSS, which features the leaders of the
industry in both Sweden and the U.S., is an ideal and effective forum."
Key participants at this year's summit include:
-- Jacob Wallenberg, CEO, Investor AB
-- Andy Davies, Director, Business Development, Amgen
-- Dr. William Haseltine, Chairman, Haseltine Global Health
-- Dr. Doug Fambrough, Partner, Oxford Biosciences
-- Niklas Prager, CEO, Pfizer AB
-- Peter Kash, Chairman, Two River Group Holdings
-- Glen Giovanetti, Head of Life Sciences, Ernst & Young
-- Robert Charpentier, CEO, Kaupthing Bank
-- Professor Mathias Uhlén, Royal Institute of Technology in Stockholm
-- William Gedale, Managing Partner, NGN Capital
-- Professor Hans Wigzell, Karolinska Development
-- Dr. Ellen Strahlman, Sr. Vice President & Chief Medical Officer of
GlaxoSmithKline
Contact Information: For more information, please contact:
Barbro Ehnbom
Chairman SALSS
+46 8 736 9335
+46 70 593 8335
Udayan Gupta
Moderator SALSS
+1 917 497 84 07
www.swedishamericanlifescience.com